Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 2/20 | 0.42 |
| ▸ | GNPAT | O15228 | 1/20 | 0.41 |
| ▸ | BMP1 | P13497 | 3/20 | 0.36 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.36 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.36 |
| ▸ | PTPRA | P18433 | 1/20 | 0.36 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.36 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.36 |
| ▸ | HRH1 | P35367 | 1/20 | 0.35 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.34 |
| ▸ | ECE1 | P42892 | 1/20 | 0.34 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13402953 | 0.94 | MME (0.42) | MMEGNPATBMP1TGFBR1PTPN1 | |
| SCHEMBL13402957 | 0.86 | GNPAT (0.45) | MMEGNPATBMP1PTPN1PTPN2 | |
| SCHEMBL13402943 | 0.86 | GNPAT (0.45) | MMEGNPATBMP1PTPN1PTPN2 | |
| SCHEMBL16494295 | 0.85 | GNPAT (0.56) | MMEGNPATTGFBR1PTPN1PTPN2 | |
| SCHEMBL27857327 | 0.85 | GNPAT (0.56) | MMEGNPATTGFBR1PTPN1PTPN2 | |
| SCHEMBL13402926 | 0.83 | NMT2 (0.45) | GNPATPTPN1HRH1SIRT5 | |
| SCHEMBL13402935 | 0.79 | NMT2 (0.43) | GNPATHRH1SIRT5 | |
| SCHEMBL14490960 | 0.78 | SLC22A6 (0.36) | GNPATBMP1ENPEP | |
| SCHEMBL8729434 | 0.78 | SLC22A6 (0.36) | GNPATBMP1ENPEP | |
| SCHEMBL16348723 | 0.78 | SLC22A6 (0.36) | GNPATBMP1ENPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100105567-A1 | NOVEL CAPTURE AGENTS FOR BINDING A LIGAND | SHARP KABUSHIKI KAISHA (JP) | 2010-04-29 | — | — | US | disclosed |
| US-20090312192-A1 | METHOD FOR FUNCTIONALISING A HYDROPHOBIC SUBSTRATE | SHARP KABUSHIKI KAISHA (JP) | 2009-12-17 | — | — | US | disclosed |
| US-20090192048-A1 | METHOD OF PRODUCING A MULTIMERIC CAPTURE AGENT FOR BINDING A LIGAND | SHARP KABUSHIKI KAISHA (JP) | 2009-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105567-A1 | NOVEL CAPTURE AGENTS FOR BINDING A LIGAND | MST1R, CCL2, DNPEP | MME 120/4885GNPAT 3762/4885BMP1 995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.